益气活血通络汤加减治疗轻中度急性脑梗死的临床疗效观察  

Observation on the clinical efficacy in the treatment of patients with mild to moderate acute cerebral infarction with modified Yiqi Huoxue Tongluo decoction

作　　者：高霖 沈海鹏 徐鲜花 兰树华 吴秋鸿 张广政 GAO Lin;SHEN Haipeng;XU Xianhua;LAN Shuhua;WU Qiuhong;ZHANG Guangzheng(Department of Encephalopathy,Longyan Hospital of Traditional Chinese Medicine,Fujian,Longyan 364000,China)

机构地区：[1]福建省龙岩市中医院脑病科,福建龙岩364000

出　　处：《中国医药科学》2024年第23期120-124,共5页China Medicine And Pharmacy

基　　金：福建省龙岩市科技计划项目(2022LYF17066)。

摘　　要：目的观察益气活血通络汤治疗轻中度急性脑梗死的临床效果。方法选取2022年9月至2024年4月就诊于龙岩市中医院的100例轻中度急性脑梗死患者作为研究对象,依据患者发病时间分为溶栓组与非溶栓组,各自按照随机数表法分组,其中溶栓组30例,分为溶栓治疗组15例、溶栓对照组15例;非溶栓组70例,分为非溶栓治疗组35例、非溶栓对照组35例。对照组均予常规西医治疗,治疗组在对照组的基础上给予益气活血通络汤治疗,疗程2周。比较治疗前后的临床疗效、美国国立卫生研究院卒中量表(NHISS)评分、改良Barthel指数(MBI)评分以及不良反应发生情况。结果治疗2周后,溶栓治疗组和溶栓对照组临床疗效、NHISS评分、MBI评分以及不良反应总发生率比较,差异无统计学意义(P>0.05)。非溶栓治疗组临床疗效优于非溶栓对照组,差异有统计学意义(P<0.05);治疗2周后,非溶栓治疗组NHISS评分低于非溶栓对照组,MBI评分高于非溶栓对照组,差异有统计学意义(P<0.05);但两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论较常规西医治疗,益气活血通络汤治疗超溶栓时间窗的轻中度急性脑梗死患者能够提高临床疗效,减轻患者临床症状,提高患者生活自理能力。Objective To observe the clinical efficacy in the treatment of patients with mild to moderate acute cerebral infarction with modified Yiqi Huoxue Tongluo decoction.Methods A total of 100 patients with mild to moderate acute cerebral infarction admitted to Longyan Hospital of Traditional Chinese Medicine from September 2022 to April 2024 were selected as the research object,and they were divided into the thrombolytic group(n=30)and the non-thrombolytic group(n=70)according to the onset time of the patients.Respectively,according to the random number table method,the thrombolytic group was divided into the thrombolytic treatment group(n=15)and the thrombolytic control group(n=15),and the non-thrombolytic group was divided into the non-thrombolytic treatment group(n=35)and the non-thrombolytic control group(n=35).The control group was all treated with conventional western medicine,while the treatment group was treated with Yiqi Huoxue Tongluo decoction on the basis of the control group.The course of treatment was 2 weeks.The clinical efficacy,National Institutes of Health Stroke scale(NHISS)score,modified Barthel index(MBI)score and adverse reactions were compared before and after treatment.Results After 2 weeks of treatment,there was no statistically significant difference between the thrombolytic treatment group and the thrombolytic control group in terms of clinical efficacy,NHISS score,MBI score and total incidence of adverse reactions(P>0.05).The clinical efficacy of the non-thrombolytic treatment group was better than that of the non-thrombolytic control group,and the difference was statistically significant(P<0.05).After 2 weeks of treatment,the NHISS score of the non-thrombolytic treatment group was lower than that of the non-thrombolytic control group,and the MBI score was higher than that of the non-thrombolytic control group,and the difference was statistically significant(P<0.05).However,when comparing the total incidence rate of adverse reactions between the two groups,the difference was not statistical

关 键 词：急性脑梗死 中医 益气活血通络汤 神经功能 

分 类 号：R277.7[医药卫生—中医学]